The role of autoimmunity in obliterative bronchiolitis after lung transplantation.
The role of autoimmunity in obliterative bronchiolitis after lung transplantation.
复制标题
DOI：
10.1152/ajplung.00378.2012
复制
发表时间：
2013-03
期刊：
影响因子：
--
通讯作者：
D. Weber;D. Wilkes
中科院分区：
文献类型：
--
作者：
D. Weber;D. Wilkes
肺移植于20世纪60年代首次实施，并在80年代取得长期成功，至今仍是终末期肺部疾病唯一确定的治疗选择。慢性肺排斥，病理上归类为闭塞性毛细支气管炎(OB)，临床上称为闭塞性细支气管炎综合征，是肺移植的限制因素，使肺移植的5年存活率明显低于其他实体器官移植。最初，OB主要归因于对供体抗原的免疫反应，即同种免疫。然而，最近的工作证明了自身免疫在肺移植排斥反应过程中的作用。IL-17和自身抗原如V型胶原和K-α-1微管蛋白参与了慢性排斥反应的发生。最后，这篇翻译综述讨论了自身免疫在OB和肺移植排斥反应发展中的作用，然后讨论了治疗干预的选择。
First performed in the 1960s with long-term successes achieved in the 1980s, lung transplantation remains the only definitive treatment option for end-stage lung disease. Chronic lung rejection, pathologically classified as obliterative bronchiolitis (OB) with its clinical correlate referred to as bronchiolitis obliterans syndrome, is the limiting factor than keeps 5-yr survival rates for lung transplant significantly worse than for other solid organ transplants. Initially, OB was largely attributed to immune responses to donor antigens, alloimmunity. However, more recent work has demonstrated the role of autoimmunity in the process of lung transplant rejection. IL-17 and autoantigens such as collagen type V and K-α1 tubulin have been implicated in the development of chronic rejection. Ultimately, this translational review discusses the role that autoimmunity plays in the development of OB and lung transplant rejection and then discusses options for therapeutic intervention.